コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 enabling the reduction of membrane-inserted mycobactin.
2 cells of the deferri form of the siderophore mycobactin.
3 Mutant strain LUN9 produced no detectable mycobactin.
4 was not known to participate in synthesis of mycobactin.
5 l dimycocerosates, phenolic glycolipids, and mycobactins.
6 nown as MbtA involved in biosynthesis of the mycobactins.
7 btA which is involved in biosynthesis of the mycobactins.
8 ted in the cell wall of M. tuberculosis: the mycobactins.
9 n-binding molecules, and to transfer iron to mycobactins.
12 rain produced measurable amounts of excreted mycobactin, although both excreted exochelin (the mycoba
13 angstrom into the periplasm is essential for mycobactin and bedaquiline efflux by MmpL4 and MmpL5.
15 synthesize iron chelating siderophores named mycobactin and carboxymycobactin to extract intracellula
19 uces two classes of siderophore, lipid-bound mycobactin and water-soluble carboxymycobactin(2,3).
20 n low-iron medium and that secretion of both mycobactins and carboxymycobactins is drastically reduce
22 y, we demonstrated the presence of 1 or both mycobactins and/or tuberculosinyladenosine in serum and
23 several biosynthetic pathways (pyrimidines, mycobactin, and polyketides); genes that encode enzymes
26 icroscopy structures of MmpL4 and identify a mycobactin binding site, which is accessible from the cy
27 tuberculosis and establishes the enzymes of mycobactin biosynthesis as novel targets for the develop
28 osis catalyzes the initial transformation in mycobactin biosynthesis by converting chorismate to sali
29 cyl-AMP ligase (MbtA), the first gene in the mycobactin biosynthesis gene cluster, providing a possib
30 MbtA catalyzes the first committed step of mycobactin biosynthesis in Mycobacterium tuberculosis (M
31 he mbt cluster to evaluate the importance of mycobactin biosynthesis in the growth and virulence of M
32 ting enzyme MbtA catalyzes the first step of mycobactin biosynthesis in two half-reactions: activatio
33 novel lead compounds 44 and 49 as potential mycobactin biosynthesis inhibitors against mycobacteria.
34 rmore, a succinct discussion on non-specific mycobactin biosynthesis inhibitors and the Trojan horse
36 n vivo essentiality makes this less explored mycobactin biosynthesis pathway a promising endogenous t
38 te synthase MbtI catalyzes the first step of mycobactin biosynthesis through the conversion of the pr
39 which is responsible for the second step of mycobactin biosynthesis, exhibited potent antitubercular
44 he absence of Esx-3, mycobacteria synthesize mycobactin but are unable to use the bound iron and are
45 synthetic standards to natural mycobacterial mycobactins by nuclear magnetic resonance and mass spect
47 luster, providing a possible explanation for mycobactin dependence of Map; and Map-specific sequences
48 tant (MtbDeltambtE) was unable to synthesize mycobactins, displayed an altered colony morphology, and
51 fer from each other and from water insoluble mycobactins in polarity, which is dependent primarily up
54 ns but not iron transferrin transfer iron to mycobactins in the cell wall underscores the importance
57 dge, these are the first rationally designed mycobactin inhibitors to demonstrate an excellent in viv
58 of all 109 isolates were confirmed by using mycobactin J dependence and characterization of five wel
59 Exogenous addition of sodium propionate or Mycobactin J restored PDIM/PGL production in the Deltamb
60 ented with 1% egg yolk emulsion, 4 microg of mycobactin J, and 0.5% pyruvate (12B/EMP) for use in con
61 in the presence of a panel of siderophores (mycobactin J, deferrioxamine B, acinetoferrin, and nanno
62 sed solid medium was also used that included mycobactin J, pyruvate, and VAN but excluded the egg yol
67 ysis of CD1a cocrystallized with a synthetic mycobactin lipopeptide at 2.8 A resolution further revea
68 spectroscopy studies suggested that the LUN8 mycobactin may have an altered fatty acid side chain.
69 osis) produces two aryl-capped siderophores, mycobactin (MBT) and carboxymycobactin (cMBT), to chelat
72 d type when the medium was supplemented with mycobactins or when MtbDeltambtE was genetically complem
74 ther each of nine mbt genes was required for mycobactin production and to examine the conservation of
80 K, a conserved acyl-transferase required for mycobactin siderophore synthesis and virulence, was requ
82 mutations lead to altered concentrations of mycobactin siderophores and acylated sulfoglycolipids.
83 s-specific, small molecules as biomarkers: 2 mycobactin siderophores and tuberculosinyladenosine.
87 tion of the iron-dependent regulator (ideR), mycobactin synthase B (mbtB), or mycobactin synthase G (
90 o acids with homology to the MbtH protein of mycobactin synthesis in Mycobacteria tuberculosis; no fu
94 hain on the core structure of exochelins and mycobactins, the principal determinant of their polarity
96 logues that partially mimic the structure of mycobactin, to address the requirement of novel therapeu
97 rculosis, generates a salicyl-capped peptide mycobactin under iron-stress conditions in host macropha
98 ty that the transfer iron from exochelins to mycobactins was influenced by their polarity, we investi
99 riction and that these microvesicles contain mycobactin, which can serve as an iron donor and support
100 the first committed biosynthetic step of the mycobactins, which are important virulence factors assoc
101 -reconstituted IrtAB is sufficient to import mycobactins, which are then reduced by the siderophore i